Ebola Vaccine Arrives Amidst DRC's Deadliest Outbreak

The Democratic Republic of Congo received over 16,000 doses of the Ervebo Ebola vaccine late on August 21, 2026. This crucial delivery comes as the country grapples with its most devastating Ebola outbreak, declared on May 15, 2026, which has already recorded over 5,290 cases and 2,516 deaths. The current outbreak is spreading at an unprecedented speed, particularly in the less accessible northern and eastern regions. The World Health Organization (WHO) is making a total of 70,000 Ervebo doses available to the DRC, with 20,000 designated for a clinical trial and 50,000 for frontline health workers. The Ervebo vaccine, produced by Merck, is approved for the Zaire strain of Ebola but its efficacy against the currently circulating Bundibugyo strain is not yet fully confirmed. Early data, however, suggests potential cross-protection.

Health Minister Samuel Roger Kamba highlighted the vaccine's previous large-scale use during the 2018-2020 outbreak. Experts are exploring if Ervebo offers cross-protection, while two other vaccines specifically targeting the Bundibugyo strain are in clinical trials, developed by Moderna and the University of Oxford. An additional promising vaccine candidate is being developed by Hilleman Laboratories. The UN's senior Ebola coordinator warned that the outbreak is growing exponentially, emphasizing the urgent need for effective containment strategies and treatments. Ebola, transmitted via bodily fluids, causes fever and has caused over 15,000 deaths across Africa in the past 50 years.